Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled, Single-ascending-dose Study in Healthy Volunteers and a Double-blind (Sponsor-unblinded), Placebo-controlled, Multiple-ascending-dose Study in Patients With Parkinson's Disease to Evaluate the Safety, Tolerability, and PK/PD of LY3962681

NCT06565195 is registered in ClinicalTrials.gov with Prevail Therapeutics as lead sponsor.

NCT NCT06565195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06565195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled, Single-ascending-dose Study in Healthy Volunteers and a Double-blind (Sponsor-unblinded), Placebo-controlled, Multiple-ascending-dose Study in Patients With Parkinson's Disease to Evaluate the Safety, Tolerability, and PK/PD of LY3962681
Lead sponsor
Prevail Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
August 27, 2024
Completion date
July 23, 2030
Enrollment
124 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease